Drug Profile
Sampatrilat
Alternative Names: UK 81252Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure; Hypertension
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 19 May 2003 No development reported - Phase-II for Congestive heart failure in United Kingdom (unspecified route)
- 19 May 2003 No development reported - Phase-II for Hypertension in United Kingdom (unspecified route)